Navigation Links
Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan
Date:2/7/2013

PASADENA, Calif., Feb. 7, 2013 /PRNewswire/ --

Immunotech Laboratories, Inc. (PINKSHEETS : IMMB ) Immunotech Laboratories, Inc., today announced the appointment of Mr. Valentin Dimitrov to the company Board of Directors as Chief Financial Advisor effective immediately.

Mr. Dimitrov (48) has an impressive professional history in the International Pharmaceutical World along with an impressive background in the formation and management of International Corporations, including the founding member and supervisory Board Chairman of the International Orthodox Bank – (present "Investbank" JSC).

Immunotech Director Bo Linton , further commented Mr. Dimitrov has an extensive knowledge of the Immunotech "IPF" patented technology and has worked alongside the company for several years, assisting with International awareness and potential Clinical Trial progression for the company's Immunotherapy Treatments.

Immunotech President Harry Zhabilov commented, "We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the 'IPF' technology."

The appointment of Mr. Dimitrov to Immunotech's Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required.About Valentin Lordanov DimitrovEDUCATION:Kliment Ohridski University

Master's degree - Social PedagogicsKiev State University, Ukraine

Bachelor of International Diplomatic RelationsSPECIALIZATIONS:1995:

University of National and World Economy – Sofia - Finances1999:

Chemical-technological University - Sofia - Organic chemistry LANGUAGES:English - Fluent , Russian - fluent , German – spokenPROFESSIONAL BACKGROUND:2007-Current: "Vital-Fe" LTD – Distribution of bio-technology and pharmaceutical products – Director2003-Present"Bulgarian Association of Chemical and Fertilizer Industry" – Chairman2002-2003"Chimco Vienna" GmbH – Distributor of chemical and pharmaceutical products – Director1999-2002"CHIMCO" JSC, Vratza - Chemical production plant - Chairman of the Board of Directors1992-1998"Prima Gas" JSC – supply of natural gas – Director1995-1996"International Orthodox Bank" – (present "Investbank" JSC), Founder and member of the Supervisory Board1994-1995"Private Agricultural and Investment Bank" – Member of the Supervisory Board1990-1991 "Pharmachem" JSC – pharmaceutical and chemical industry – Director of DepartmentSafe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:
ir@immunotechlab.com

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup  

CSNNewswire – Be Seen
www.csnnewswire.com


'/>"/>
SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
2. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
3. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
4. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
5. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
6. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
7. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
8. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
9. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
10. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
11. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):